Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Birtamimab by Prothena Corp for Primary Systemic Amyloidosis: Likelihood of Approval
Birtamimab is under clinical development by Prothena Corp and currently in Phase III for Primary Systemic Amyloidosis. According to GlobalData,...